ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AGRX Agile Therapeutics Inc

0.6022
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Agile Therapeutics Inc NASDAQ:AGRX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.6022 0.27 0.2994 0 01:00:00

Agile Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on Thursday, May 11, 2023

08/05/2023 1:00pm

GlobeNewswire Inc.


Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart


From May 2023 to May 2024

Click Here for more Agile Therapeutics Charts.

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report first quarter 2023 financial results after the market close on Thursday, May 11, 2023. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss the Company’s financial results and provide a business update.

EventAgile Therapeutics First Quarter 2023 Financial Results Conference Call
DateThursday, May 11, 2023
Time4:30 p.m. ET / 1:30 p.m. PT
  

A live webcast of the conference call may be accessed via the Investor Relations portion of the Agile Therapeutics website at https://ir.agiletherapeutics.com/events-and-presentations. To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call.

About Agile Therapeutics, Inc.

Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol) transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website, Twitter account (@agilether), and LinkedIn account.

Contact:Matt RileyHead of Investor Relations & Corporate Communicationsmriley@agiletherapeutics.com

1 Year Agile Therapeutics Chart

1 Year Agile Therapeutics Chart

1 Month Agile Therapeutics Chart

1 Month Agile Therapeutics Chart

Your Recent History

Delayed Upgrade Clock